ASCOT-BPLAAnglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm
References in periodicals archive ?
In the ASCOT-BPLA study, there was a 30% increased incidence of new onset diabetes in the [beta]-blocker (atenolol) arm when compared to the amlodipine arm (7).
The CAFE study included approximately 2,200 patients recruited from five ASCOT-BPLA study centers in the United Kingdom and Ireland.
For the investigators, given the evidence from ASCOT-BPLA and previous trials, it seems that the beneficial effect of the amlodipine/perindopril regimen is largely a composition of the protective effect of Coversyl, amlodipine playing a neutral role, whereas atenolol and thiazide have adverse effects.
This new ASCOT-BPLA analyses provide robust evidence that treating hypertensive patients with a regimen based on amlodipine and perindopril in comparison to atenolol and thiazide significantly reduces the risk of NOD," states Dr Ajay Gupta, lead author and Research Fellow at the International Centre for Circulatory Health, Heart & Lung Institute, Imperial College, London.
ASCOT-BPLA was a major multinational trial involving over 19,000 hypertensive patients that compared the effectiveness of two different treatment strategies at reducing cardiovascular events.
The aim of the new analysis of ASCOT-BPLA data was to determine the baseline predictors of NOD in a large population of patients with hypertension and to develop a risk score to detect those at high risk for NOD.